<p>根據 Handelsbanken Fonder AB 最近向 SEC 提交的 13F 文件，該公司在 2023 年第二季度將其在 Illumina, Inc.（NASDAQ:ILMN - 免費報告）的持股比例降低了 54.3%。該公司在此期間出售了 47,932 股後，持有 40,400 股這家生命科學公司的股票。Handelsbanken Fonder AB 在 Illumina 的持股在最近一個季度末價值為 3,855,000 美元。</p>
<ul>
<li>GRAIL：瞄準 1000 億美元癌症市場的生物科技股票</li>
</ul>
<p>其他一些機構投資者和對沖基金也買賣了 ILMN 的股票。Corvex Management LP 在第一季度將其在 Illumina 的持股比例增加了 125.2%。Corvex Management LP 現在擁有 3,829,608 股這家生命科學公司的股票，價值為 303,841,000 美元，此前在上個季度又購買了 2,129,449 股。AQR Capital Management LLC 在第一季度將其在 Illumina 的持股增加了 361.7%。AQR Capital Management LLC 現在擁有 2,121,585 股這家生命科學公司的股票，價值為 165,484,000 美元，此前在上個季度又購買了 1,662,093 股。Jacobs Levy Equity Management Inc.在第一季度將其在 Illumina 的持股增加了 11,714.9%。Jacobs Levy Equity Management Inc.現在擁有 1,161,882 股這家生命科學公司的股票，價值為 92,184,000 美元，此前在上個季度又收購了 1,152,048 股。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度將其在 Illumina 的持股增加了 51.7%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 現在擁有 1,960,385 股這家生命科學公司的股票，價值為 155,537,000 美元，此前在上個季度又收購了 667,978 股。最後，PGGM Investments 在第二季度將其在 Illumina 的持股增加了 115.1%。PGGM Investments 現在擁有 1,149,408 股這家生命科學公司的股票，價值為 109,665,000 美元，此前在上個季度又收購了 614,973 股。89.42% 的股票由機構投資者持有。</p>
<h2>華爾街分析師觀點</h2>
<p>最近，一些分析師對 ILMN 股票發表了看法。Weiss Ratings 在 10 月 8 日的報告中重申了對 Illumina 股票的 “賣出（d+）” 評級。巴克萊在 10 月 31 日的研究報告中將 Illumina 的目標價從 95.00 美元上調至 100.00 美元，並給予該股票 “減持” 評級。大和資本市場在 8 月 12 日的研究報告中將 Illumina 的評級從 “跑贏大盤” 下調至 “中性”，並設定了 94.00 美元的目標價。瑞銀集團在 10 月 31 日的報告中將 Illumina 的目標價從 110.00 美元上調至 120.00 美元，並給予該股票 “中性” 評級。最後，Cowen 在 10 月 31 日的研究報告中重申了對 Illumina 股票的 “持有” 評級。五位研究分析師對該股票給予了買入評級，十二位給予了持有評級，三位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，平均目標價為 115.00 美元。</p>
<ul>
<li>戰略性買入點亮這隻生物科技股票：是時候投資了嗎？</li>
</ul>
<p><strong>查看我們關於 Illumina 的最新報告</strong></p>
<h2>Illumina 股價上漲 1.7%</h2>
<p>NASDAQ ILMN 的股票在週二開盤時為 125.96 美元。Illumina, Inc.的 12 個月最低價為 68.70 美元，最高價為 153.06 美元。該公司的市值為 192.5 億美元，市盈率為 15.94，市盈增長比率為 2.34，貝塔值為 1.42。該公司的 50 日簡單移動平均線為 105.72 美元，200 日簡單移動平均線為 98.01 美元。公司的速動比率為 1.41，流動比率為 1.81，債務與股本比率為 0.66。</p>
<ul>
<li>Palantir 未能進入標準普爾 500 指數；它仍然看起來像是一個買入機會</li>
</ul>
<p>Illumina（NASDAQ:ILMN - 獲取免費報告）最近在 10 月 30 日宣佈了其季度財報。這家生命科學公司報告的每股收益為 1.34 美元，超出市場共識預期的 1.16 美元，超出 0.18 美元。該公司在本季度的收入為 10.8 億美元，而分析師預期為 10.7 億美元。Illumina 的淨利潤率為 29.36%，股本回報率為 28.93%。與去年同期相比，該公司的收入增長了 0.4%。在去年同期，該公司每股收益為 1.14 美元。Illumina 已將其 2025 財年的指導目標設定為 4.650-4.750 每股收益。分析師預計 Illumina, Inc.在當前財年將發佈 4.51 美元的每股收益。</p>
<h2>內部人士下注</h2>
<p>在其他 Illumina 新聞中，董事 Scott Gottlieb 在 11 月 3 日的交易中購買了 500 股該公司的股票。該股票的平均購買成本為每股 122.13 美元，總交易額為 61,065.00 美元。購買後，該董事在公司中持有 12,523 股，價值約為 1,529,433.99 美元。此次交易使其持股增加了 4.16%。該購買在向證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。內部人士持有公司 2.60% 的股票。</p>
<h2>Illumina 公司簡介</h2>
<p>（免費報告）</p>
<p>Illumina, Inc.在美國、新加坡、英國及國際市場提供基於測序和陣列的遺傳和基因組分析解決方案。它通過核心 Illumina 和 GRAIL 兩個部門運營。該公司提供測序和陣列基礎的儀器和耗材，包括試劑、流動池和文庫準備；全基因組測序套件，能夠測序各種規模和複雜度的整個基因組；以及靶向重測序套件，能夠測序外顯子、特定基因和 RNA 或其他感興趣的基因組區域。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票超過 Illumina</li>
<li>如何利用分析師評級進行交易</li>
<li>D-Wave：是時候買入了嗎？還是下跌才剛剛開始？</li>
<li>如何選擇高評級股票</li>
<li>Hims、Block 和 NRG 剛剛啓動了大規模股票回購</li>
<li>什麼是稀釋每股收益（Diluted EPS）？</li>
<li>零售財報匯總：沃爾瑪表現出色，塔吉特在第三季度下滑</li>
</ul>
<p><strong>想看看其他對 ILMN 感興趣的對沖基金持有哪些股票嗎？</strong> 訪問 HoldingsChannel.com 獲取 Illumina, Inc.（NASDAQ:ILMN - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUxNTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUxNTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Illumina 嗎？</h2>
<p>在考慮 Illumina 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Illumina 並不在名單上。</p>
<p>雖然 Illumina 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ILMN

<p>Handelsbanken Fonder AB 在第二季度減少了對 Illumina, Inc. 的持股，減持幅度為 54.3%，出售了 47,932 股。Illumina 的股票分析師評級不一，目前的平均評級為 “持有”，目標價格為 115.00 美元。該股票開盤價為 125.96 美元，12 個月的價格區間為 68.70 美元至 153.06 美元。Illumina 報告第三季度每股收益為 1.34 美元，超出預期</p>

<p>Handelsbanken Fonder AB lowered its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 54.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 40,400 shares of the life sciences company's stock after selling 47,932 shares during the period. Handelsbanken Fonder AB's holdings in Illumina were worth $3,855,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據 Handelsbanken Fonder AB 最近向 SEC 提交的 13F 文件，該公司在 2023 年第二季度將其在 Illumina, Inc.（NASDAQ:ILMN - 免費報告）的持股比例降低了 54.3%。該公司在此期間出售了 47,932 股後，持有 40,400 股這家生命科學公司的股票。Handelsbanken Fonder AB 在 Illumina 的持股在最近一個季度末價值為 3,855,000 美元。</p>
</div><ul>
<li>GRAIL: Biotech Stock Targeting $100B Cancer Market</li>
</ul>
<div class="lb-trans"><ul>
<li>GRAIL：瞄準 1000 億美元癌症市場的生物科技股票</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. Corvex Management LP grew its position in shares of Illumina by 125.2% during the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company's stock valued at $303,841,000 after purchasing an additional 2,129,449 shares in the last quarter. AQR Capital Management LLC grew its holdings in Illumina by 361.7% during the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company's stock valued at $165,484,000 after buying an additional 1,662,093 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Illumina by 11,714.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company's stock worth $92,184,000 after acquiring an additional 1,152,048 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Illumina by 51.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company's stock worth $155,537,000 after acquiring an additional 667,978 shares in the last quarter. Finally, PGGM Investments raised its holdings in shares of Illumina by 115.1% during the 2nd quarter. PGGM Investments now owns 1,149,408 shares of the life sciences company's stock worth $109,665,000 after acquiring an additional 614,973 shares in the last quarter. 89.42% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金也買賣了 ILMN 的股票。Corvex Management LP 在第一季度將其在 Illumina 的持股比例增加了 125.2%。Corvex Management LP 現在擁有 3,829,608 股這家生命科學公司的股票，價值為 303,841,000 美元，此前在上個季度又購買了 2,129,449 股。AQR Capital Management LLC 在第一季度將其在 Illumina 的持股增加了 361.7%。AQR Capital Management LLC 現在擁有 2,121,585 股這家生命科學公司的股票，價值為 165,484,000 美元，此前在上個季度又購買了 1,662,093 股。Jacobs Levy Equity Management Inc.在第一季度將其在 Illumina 的持股增加了 11,714.9%。Jacobs Levy Equity Management Inc.現在擁有 1,161,882 股這家生命科學公司的股票，價值為 92,184,000 美元，此前在上個季度又收購了 1,152,048 股。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度將其在 Illumina 的持股增加了 51.7%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 現在擁有 1,960,385 股這家生命科學公司的股票，價值為 155,537,000 美元，此前在上個季度又收購了 667,978 股。最後，PGGM Investments 在第二季度將其在 Illumina 的持股增加了 115.1%。PGGM Investments 現在擁有 1,149,408 股這家生命科學公司的股票，價值為 109,665,000 美元，此前在上個季度又收購了 614,973 股。89.42% 的股票由機構投資者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of analysts have recently weighed in on ILMN shares. Weiss Ratings restated a &#34;sell (d+)&#34; rating on shares of Illumina in a report on Wednesday, October 8th. Barclays boosted their price objective on Illumina from $95.00 to $100.00 and gave the stock an &#34;underweight&#34; rating in a research note on Friday, October 31st. Daiwa Capital Markets lowered Illumina from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $94.00 price objective for the company. in a research note on Tuesday, August 12th. UBS Group lifted their target price on Illumina from $110.00 to $120.00 and gave the stock a &#34;neutral&#34; rating in a report on Friday, October 31st. Finally, Cowen reissued a &#34;hold&#34; rating on shares of Illumina in a research report on Friday, October 31st. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $115.00.</p>
<div class="lb-trans"><p>最近，一些分析師對 ILMN 股票發表了看法。Weiss Ratings 在 10 月 8 日的報告中重申了對 Illumina 股票的 “賣出（d+）” 評級。巴克萊在 10 月 31 日的研究報告中將 Illumina 的目標價從 95.00 美元上調至 100.00 美元，並給予該股票 “減持” 評級。大和資本市場在 8 月 12 日的研究報告中將 Illumina 的評級從 “跑贏大盤” 下調至 “中性”，並設定了 94.00 美元的目標價。瑞銀集團在 10 月 31 日的報告中將 Illumina 的目標價從 110.00 美元上調至 120.00 美元，並給予該股票 “中性” 評級。最後，Cowen 在 10 月 31 日的研究報告中重申了對 Illumina 股票的 “持有” 評級。五位研究分析師對該股票給予了買入評級，十二位給予了持有評級，三位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，平均目標價為 115.00 美元。</p>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>戰略性買入點亮這隻生物科技股票：是時候投資了嗎？</li>
</ul>
</div><p><strong>View Our Latest Report on Illumina</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Illumina 的最新報告</strong></p>
</div><h2>Illumina Trading Up 1.7%</h2>
<div class="lb-trans"><h2>Illumina 股價上漲 1.7%</h2>
</div><p>Shares of NASDAQ ILMN opened at $125.96 on Tuesday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06. The firm has a market cap of $19.25 billion, a PE ratio of 15.94, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The business has a fifty day simple moving average of $105.72 and a two-hundred day simple moving average of $98.01. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66.</p>
<div class="lb-trans"><p>NASDAQ ILMN 的股票在週二開盤時為 125.96 美元。Illumina, Inc.的 12 個月最低價為 68.70 美元，最高價為 153.06 美元。該公司的市值為 192.5 億美元，市盈率為 15.94，市盈增長比率為 2.34，貝塔值為 1.42。該公司的 50 日簡單移動平均線為 105.72 美元，200 日簡單移動平均線為 98.01 美元。公司的速動比率為 1.41，流動比率為 1.81，債務與股本比率為 0.66。</p>
</div><ul>
<li>Palantir Was Left Out of the S&amp;P 500; It Still Looks Like a Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Palantir 未能進入標準普爾 500 指數；它仍然看起來像是一個買入機會</li>
</ul>
</div><p>Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company's revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Illumina（NASDAQ:ILMN - 獲取免費報告）最近在 10 月 30 日宣佈了其季度財報。這家生命科學公司報告的每股收益為 1.34 美元，超出市場共識預期的 1.16 美元，超出 0.18 美元。該公司在本季度的收入為 10.8 億美元，而分析師預期為 10.7 億美元。Illumina 的淨利潤率為 29.36%，股本回報率為 28.93%。與去年同期相比，該公司的收入增長了 0.4%。在去年同期，該公司每股收益為 1.14 美元。Illumina 已將其 2025 財年的指導目標設定為 4.650-4.750 每股收益。分析師預計 Illumina, Inc.在當前財年將發佈 4.51 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Illumina news, Director Scott Gottlieb acquired 500 shares of the firm's stock in a transaction on Monday, November 3rd. The stock was acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the purchase, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The purchase was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own 2.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Illumina 新聞中，董事 Scott Gottlieb 在 11 月 3 日的交易中購買了 500 股該公司的股票。該股票的平均購買成本為每股 122.13 美元，總交易額為 61,065.00 美元。購買後，該董事在公司中持有 12,523 股，價值約為 1,529,433.99 美元。此次交易使其持股增加了 4.16%。該購買在向證券交易委員會的法律文件中披露，可以通過此超鏈接訪問。內部人士持有公司 2.60% 的股票。</p>
</div><h2>Illumina Company Profile</h2>
<div class="lb-trans"><h2>Illumina 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.</p>
<div class="lb-trans"><p>Illumina, Inc.在美國、新加坡、英國及國際市場提供基於測序和陣列的遺傳和基因組分析解決方案。它通過核心 Illumina 和 GRAIL 兩個部門運營。該公司提供測序和陣列基礎的儀器和耗材，包括試劑、流動池和文庫準備；全基因組測序套件，能夠測序各種規模和複雜度的整個基因組；以及靶向重測序套件，能夠測序外顯子、特定基因和 RNA 或其他感興趣的基因組區域。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Illumina</li>
<li>How to trade using analyst ratings</li>
<li>D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?</li>
<li>How to Choose Top Rated Stocks</li>
<li>Hims, Block, and NRG Just Launched Huge Stock Buybacks</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Illumina</li>
<li>如何利用分析師評級進行交易</li>
<li>D-Wave：是時候買入了嗎？還是下跌才剛剛開始？</li>
<li>如何選擇高評級股票</li>
<li>Hims、Block 和 NRG 剛剛啓動了大規模股票回購</li>
<li>什麼是稀釋每股收益（Diluted EPS）？</li>
<li>零售財報匯總：沃爾瑪表現出色，塔吉特在第三季度下滑</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ILMN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 ILMN 感興趣的對沖基金持有哪些股票嗎？</strong> 訪問 HoldingsChannel.com 獲取 Illumina, Inc.（NASDAQ:ILMN - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUxNTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ILMN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Illumina Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Illumina 嗎？</h2>
</div><p>Before you consider Illumina, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Illumina 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Illumina 並不在名單上。</p>
</div><p>While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Illumina 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Handelsbanken Fonder AB 出售了 47,932 股 Illumina 公司（股票代碼：ILMN）的股票